SFM
EGRX

Signet Financial Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Signet Financial Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-750
Closed -$38K – 1410
2021
Q4 		$38K Buy
+750
New +$38.9K 0.01% 589

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Signet Financial Management's EGRX Position: Q1 2022 in Review

Signet Financial Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 750 shares — an estimated $38K sold.

Signet Financial Management first reported a position in EGRX in Q4 2021 and held it in 1 quarter. The position peaked at $38K in Q4 2021. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • Signet Financial Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 750 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $38K.
  • Signet Financial Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's Eagle Pharmaceuticals, Inc. position peaked at $38K in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.